Clinical Impact of Genetic Testing for Long QT Syndrome - Evidence From a Nationwide LQTS Registry in Japan.
Aiba T, Ohno S, Takegami M, Kato Y, Sakaguchi H, Shimamoto K, Sonoda K, Ida K, Sumitomo N, Nabeshima T, Murakami T, Ninomiya Y, Kato K, Fukuyama M, Makiyama T, Hayashi K, Ohta K, Morita H, Nakajima T, Kaneko Y, Yagihara N, Otsuki S, Kosho T, Yoshida Y, Takamuro M, Ueno M, Takahashi T, Inden Y, Hayabuchi Y, Muraji S, Watanabe S, Nishimura K, Asano Y, Horigome H, Yoshinaga M, Horie M, Shimizu W, Kusano K.
Aiba T, et al.
Circ J. 2025 May 23;89(6):835-844. doi: 10.1253/circj.CJ-25-0105. Epub 2025 Mar 30.
Circ J. 2025.
PMID: 40159220
Free article.
Genetic testing using a next-generation sequencing panel and/or Sanger sequencing was performed for 3,770 (98%) patients, genotype was then identified in the following LQTS-associated genes: KCNQ1 (45%), KCNH2 (34%), SCN5A (8%), KCNE1 (0.1%), KCNE2 (0.03%), KCNJ2 (2.7%), C …
Genetic testing using a next-generation sequencing panel and/or Sanger sequencing was performed for 3,770 (98%) patients, genotype was then …